Expertise in
14
conditions

Dr. Alexander Shoushtari

Oncology
Rockefeller Outpatient Pavilion
160 E 53rd St, 
New York, NY 
Accepting New Patients
Offers Telehealth
17 Years of Experience
Expertise in
14
conditions
Rockefeller Outpatient Pavilion
160 E 53rd St, 
New York, NY 

Overview

Alexander Shoushtari is an Oncologist in New York, New York. Dr. Shoushtari has been practicing medicine for over 17 years is highly rated in 14 conditions, according to our data. His top areas of expertise are Metastatic Uveal Melanoma, Melanoma, Melanoma of the Eye, Liver Embolization, and Gastrostomy. Dr. Shoushtari is currently accepting new patients.

His clinical research consists of co-authoring 150 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year

2009

Specialties

Oncology

Licenses

Internal Medicine in NY

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Hamaspik
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Health First
  • HMO
  • POS
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MVP Health
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Rockefeller Outpatient Pavilion
160 E 53rd St, New York, NY 10022

Additional Areas of Focus

Dr. Shoushtari has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 2 Study of Vorinostat (NSC 701852) in Metastatic Uveal Melanoma
A Phase 2 Study of Vorinostat (NSC 701852) in Metastatic Uveal Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Drug
Study Drug: Vorinostat
Study Phase: Phase 2
A Phase 2 Study of the ALK Inhibitor Ensartinib for Patients With Melanomas Harboring ALK Alterations or Aberrant ALK Expression
A Phase 2 Study of the ALK Inhibitor Ensartinib for Patients With Melanomas Harboring ALK Alterations or Aberrant ALK Expression
Enrollment Status: Active_not_recruiting
Publish Date: February 05, 2026
Intervention Type: Drug, Diagnostic test
Study Drug: Ensartinib
Study Phase: Phase 2
A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma
A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: October 21, 2025
Intervention Type: Drug
Study Drugs: LXH254, LTT462, Trametinib, Ribociclib
Study Phase: Phase 2
A Randomized Two-Arm Phase II Study of Trametinib Alone and in Combination With GSK2141795 in Patients With Advanced Uveal Melanoma
A Randomized Two-Arm Phase II Study of Trametinib Alone and in Combination With GSK2141795 in Patients With Advanced Uveal Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 27, 2025
Intervention Type: Drug, Other
Study Phase: Phase 2
A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination With Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients With Advanced Melanoma
A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination With Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients With Advanced Melanoma
Enrollment Status: Withdrawn
Publish Date: July 24, 2024
Intervention Type: Drug
Study Drugs: IMCgp100, Durvalumab, Tremelimumab
Study Phase: Phase 1/Phase 2
A Phase II, Open Label, Multi-Dose Study of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients With Selected Advanced or Metastatic Solid Malignancies Who Are Scheduled to Receive Standard-of-Care Immunotherapy Only, As Single Agent or in Combination
A Phase II, Open Label, Multi-Dose Study of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients With Selected Advanced or Metastatic Solid Malignancies Who Are Scheduled to Receive Standard-of-Care Immunotherapy Only, As Single Agent or in Combination
Enrollment Status: Completed
Publish Date: July 09, 2024
Intervention Type: Drug
Study Drug: 89Zr-Df-IAB22M2C
Study Phase: Phase 2
A Multicenter Phase 1b Randomized, Placebo-controlled, Blinded Study to Evaluate the Safety, Tolerability and Efficacy of Microbiome Study Intervention Administration in Combination With Anti-PD-1 Therapy in Adult Patients With Unresectable or Metastatic Melanoma
A Multicenter Phase 1b Randomized, Placebo-controlled, Blinded Study to Evaluate the Safety, Tolerability and Efficacy of Microbiome Study Intervention Administration in Combination With Anti-PD-1 Therapy in Adult Patients With Unresectable or Metastatic Melanoma
Enrollment Status: Completed
Publish Date: June 06, 2024
Intervention Type: Drug
Study Drugs: Vancomycin Pretreatment, Nivolumab, SER-401
Study Phase: Phase 1
Phase II Trial of Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
Phase II Trial of Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
Enrollment Status: Completed
Publish Date: December 06, 2023
Intervention Type: Drug
Study Drug: Crizotinib
Study Phase: Phase 2
A Phase I/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Using the Intra-patient Escalation Dosing Regimen in Patients With Advanced Uveal Melanoma
A Phase I/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Using the Intra-patient Escalation Dosing Regimen in Patients With Advanced Uveal Melanoma
Enrollment Status: Completed
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: IMCgp100
Study Phase: Phase 1/Phase 2
A Randomized Phase II Trial of Adjuvant Nivolumab or Expectant Observation Following Neoadjuvant Ipilimumab Plus Nivolumab and Surgical Resection of High-Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
A Randomized Phase II Trial of Adjuvant Nivolumab or Expectant Observation Following Neoadjuvant Ipilimumab Plus Nivolumab and Surgical Resection of High-Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
Enrollment Status: Withdrawn
Publish Date: October 03, 2018
Intervention Type: Radiation, Procedure, Biological, Other
Study Phase: Phase 2
View 9 Less Clinical Trials

150 Total Publications

Metastatic Uveal Melanoma Surveillance: A Delphi Panel Consensus.
Metastatic Uveal Melanoma Surveillance: A Delphi Panel Consensus.
Journal: Cancers
Published: November 27, 2025
Similar Doctors
Expertise in
33
conditions
Dr. Sandra D'angelo
Oncology
Expertise in
33
conditions
Dr. Sandra D'angelo
Oncology

Rockefeller Outpatient Pavilion

160 E 53rd St, 
New York, NY 
 (0.8 miles away)
646-583-3648
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sandra D'angelo is an Oncologist in New York, New York. Dr. D'angelo is highly rated in 33 conditions, according to our data. Her top areas of expertise are Synovial Sarcoma, Adult Soft Tissue Sarcoma, Merkel Cell Carcinoma, Liposarcoma, and Liver Embolization. Dr. D'angelo is currently accepting new patients.

Expertise in
26
conditions
Dr. Steven Horwitz
Hematology | Oncology
Expertise in
26
conditions
Dr. Steven Horwitz
Hematology | Oncology

David H. Koch Center For Cancer Care At Memorial Sloan Kettering Cancer Center

530 E 74th St, 
New York, NY 
 (0.3 miles away)
646-535-8986
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Steven Horwitz is a Hematologist and an Oncologist in New York, New York. Dr. Horwitz is highly rated in 26 conditions, according to our data. His top areas of expertise are Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Non-Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, and Bone Marrow Aspiration. Dr. Horwitz is currently accepting new patients.

Expertise in
32
conditions
Dr. William Tap
Oncology
Expertise in
32
conditions
Dr. William Tap
Oncology

Rockefeller Outpatient Pavilion

160 E 53rd St, 
New York, NY 
 (0.8 miles away)
929-343-3624
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

William Tap is an Oncologist in New York, New York. Dr. Tap is highly rated in 32 conditions, according to our data. His top areas of expertise are Adult Soft Tissue Sarcoma, Gastrointestinal Stromal Tumor, Angiosarcoma, Tissue Biopsy, and Liver Embolization. Dr. Tap is currently accepting new patients.

Frequently Asked Questions about Dr. Alexander Shoushtari

How do I make an appointment with Dr. Alexander Shoushtari?

You can book an appointment with Dr. Alexander Shoushtari by calling their office at 315-275-7485. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Alexander Shoushtari a top-rated expert for Metastatic Uveal Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Alexander Shoushtari is classified as an Elite expert for Metastatic Uveal Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Alexander Shoushtari specialize in?

While Dr. Alexander Shoushtari is a Oncology, they have specific expertise in Metastatic Uveal Melanoma, Melanoma, and Melanoma of the Eye. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Alexander Shoushtari participate in research or clinical trials?

Yes. Dr. Alexander Shoushtari has published 150 articles and abstracts on conditions like Metastatic Uveal Melanoma. You can view a list of Dr. Alexander Shoushtari's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Alexander Shoushtari accept my insurance?

Dr. Alexander Shoushtari accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 315-275-7485 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Shoushtari's expertise for a condition
ConditionClose
View All 34 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile